

RESEARCH NOTE

Open Access



Molecular detection of drug resistant polymorphisms in *Plasmodium falciparum* isolates from Southwest, Nigeria

Monday Tola^{1,4†}, Olumide Ajibola^{2,5†} , Emmanuel Taiwo Idowu³, Olusesan Omidiji⁴, Samson Taiwo Awolola¹ and Alfred Amambua-Ngwa^{5*}

Abstract

Objective: Nigeria bears 25% of global malaria burden despite concerted efforts towards its control and elimination. The emergence of drug resistance to first line drugs, artemisinin combination therapies (ACTs), indicates an urgent need for continuous molecular surveillance of drug resistance especially in high burden countries where drug interventions are heavily relied on. This study describes mutations in *Plasmodium falciparum* genes associated with drug resistance in malaria; *Pfk13*, *Pfmdr1*, *PfATPase6* and *Pfcr1* in isolates obtained from 83 symptomatic malaria patients collected in August 2014, aged 1–61 years old from South-west Nigeria.

Results: Two *Pfmdr1*, N86 and Y184 variants were present at a prevalence of 56% and 13.25% of isolates respectively. There was one synonymous (S679S) and two non-synonymous (M699V, S769M) mutations in the *PfATPase6* gene, while *Pfcr1* genotype (CVIET), had a prevalence of 45%. The *Pfk13* C580Y mutant allele was suspected by allelic discrimination in two samples with mixed genotypes although this could not be validated with independent isolation or additional methods. Our findings call for robust molecular surveillance of antimalarial drug resistance markers in west Africa especially with increased use of antimalarial drugs as prophylaxis for Covid-19.

Keyword: Artemisinin, Malaria, K13, Drug resistance, Nigeria

Introduction

Malaria infects over 220 million people with at least 405,000 deaths annually, 67% of those deaths occur in children under the age of five, and 94% of deaths according to 2018 World Health Organization data occurred in Africa [1]. Drug resistance of malaria parasites to previously efficacious first line chemotherapies, chloroquine (CQ) and sulfadoxine-pyrimethamine (SP), in sub-Saharan Africa (sSA), led to replacement with artemisinin combination therapies (ACT), and complete removal of CQ [1, 2]. A single point mutation K76T, in codons

72–76 of the chloroquine resistance transporter gene (*Pfcr1*) has been the main cause of resistance to CQ [3, 4], while mutations in the dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS) were responsible for SP resistance in parasites [5, 6].

P. falciparum has also developed resistance to ACTs, which combines a fast-acting artemisinin (ART) derivative with a long-lasting partner such as Lumefantrine, Mefloquine or Amodiaquine. ACT resistance is widespread in the Greater Mekong subregion (GMS) in southeast Asia [1, 7]. Resistance to ART and its derivatives have been confirmed to be associated with mutations in Kelch-13 gene (*pfk13*). Mutations in *pfk13* have been reported in GMS, Guyana, Rwanda, and Tanzania [1]. In sSA, *pfk13* mutations are yet to be associated with partial or complete ART-resistant parasite isolates, and

*Correspondence: angwa@mrc.gm

[†]Tola Monday and Ajibola Olumide joint first authors

⁵ Medical Research Council Unit The Gambia At London, School of Hygiene and Tropical Medicine, Banjul, The Gambia

Full list of author information is available at the end of the article



ACT efficacy still remains very high. However, there have been increasing case reports of ACT failures, or delayed parasite clearance within Africa suggesting the need to investigate the factors that might be responsible [8, 9]. Mutations in *Pfmdr1* on codons 86, 184, 1246 and copy number amplifications have also been linked to susceptibility to drugs including ACTs. *P. falciparum* sarcoplasmic reticulum calcium-ATPase (SERCA) type protein encoded by a gene *PfATPase6* has been described to modulate the susceptibility of parasites to ART. PfATPase6 protein of *P. falciparum* has therefore been suggested to be a target of ARTs [10–12].

Molecular surveillance of drug resistance associated mutations, especially to ACTs is particularly relevant in Africa which bears > 90% of the deaths globally. This study describes the molecular prevalence of mutations in the drug resistant genes *Pfk13*, *Pfmdr1*, *PfATPase6* and *Pfprt* from *P. falciparum* clinical samples in Southwest Nigeria, where Arthemeter Lumefantrine has been the main first line ACT for malaria treatment over the last 15 years.

Main text

Materials and methods

Study site

This study was carried out in August 2014 in two communities—Badagry (Lagos State) and Alajue (Ede, Osun State). Badagry (6° 25' N 2° 53' E), is a coastal town with an area of 170 m² and a human population of 241,093 (NPC, 2006) that borders the Republic of Benin. Alajue village (7° 40' N 4° 30' E), is an ancient Yoruba town with a total area of 130 m² and a human population of 159,866 (NPC, 2006). Both towns are located in the south western part of Nigeria, with similar environmental conditions, occupation and lifestyle of the people.

Sampling

A total of 83 symptomatic malaria patients were recruited for this study. Following informed consent of the participants, parent or guardian, they were tested with malaria rapid diagnostic test (RDT) kit and 2 ml blood samples were collected into RNAlater. Dried blood spots (DBS) of each sample was made on 3MM Whatman filter paper.

Nucleic acid extraction

DNA from DBS was extracted using the Qiagen Mini Kit (Qiagen) according to manufacturer's instructions and stored at minus 20 °C until needed. Total RNA was isolated from whole blood stored in RNAlater using PureLink™ RNA Mini Kit (Invitrogen) following the manufacturer's instructions.

Plasmodium falciparum molecular detection

DNA from DBS of each sample was used for molecular speciation of *P. falciparum* by nested PCR through amplification of the 18S rRNA following established protocols [13]. Nest 1 amplified a large part of the 18S rRNA common to the *Plasmodium* genus, while the Nest 2 amplified a region in the genus specific for that species of *Plasmodia*. Differentiation of the species was based on amplicon band size with *P. falciparum* having a size of 205 bp. PCR fragments were detected and sized on the QIAXCEL automated electrophoresis system.

Quantitative PCR

To determine the gene expression levels of *Pfk13* and *PfATPase*, total RNA was treated to remove genomic DNA by digesting with 2 µl of DNaseI (Fermentas) and 5 µl of reaction buffer, incubated at 37 °C for 30 min and inactivated with 5 µl, 25 mM EDTA, 65 °C for 10 min. RNA purity and concentration were determined using a NanoDrop 1000™ (Thermo Scientific). cDNA was synthesised using the RNA Reverse Transcriptase kit (Invitrogen). Synthesized cDNA was quantified by qPCR on a CFX 96 (Bio-Rad) with the following cyclic conditions: 95 °C, 10 min, 49 cycles of 95 °C, 15 s and 60 °C for 90 s. Relative fold increase of specific mRNA transcripts in samples was compared to *P. falciparum* (3D7) wildtype control, normalised using the 18S rRNA housekeeping gene. Expression levels were calculated using 2^{-ΔΔCt} method. Data was analysed using at least 3 independent experiments.

pfk13 and *PfATPase* genotyping

Alleles of *Pfk13* propeller domain polymorphisms (Y493H, R539T, I543T, C580Y), and *PfATPase6* (S679S, M699V, S769M) associated with delayed clearance were determined by Taqman allelic discrimination and sequencing and list of primers used provided in Additional file 1: (Tables S1, 2). For each sample a working Master Mix was prepared to include 1× of Taqman Universal PCR Master Mix (Life Technologies), 300 nM of the forward and reverse primers, 200 nM of each allele specific probe (Additional file 1: Table S2) and at least 5 ng of DNA from DBS in 25 µl reaction volume. Amplification was done on the Bio-Rad CFX96 real-time thermocycler set to detect fluorescent emissions for 6-carboxyfluorescein (6-FAM) (mutant) and hexachloro-6-carboxyfluorescein (HEX) (wild type). Each SNP was amplified in a thermocycle of 50 °C for 2 min, 10 min of initial template denaturation and enzyme activation at 95 °C followed by 50 cycles of 92 °C for 15 s and 60 °C for 1 min. Allelic discrimination analysis was performed with the Bio-Rad CFX manager with parameters

set to subtract background and correct for fluorescent drift prior to clustering of wild or mutant amplicons. All PCRs included DNA from *P. falciparum* 3D7 as wildtype control.

Sequencing

Pfk13, PfATPase6, Pfcrt and Pfmdr1 amplicons were purified from a 0.8% agarose gel and subjected to cycle sequencing using BigDye V3.1 (details in supplementary methods section). Sequencing was done on ABI3130XL DNA analyser.

Data analysis

Descriptive statistics was carried out in Microsoft Excel 2010. Sequence alignment was done on CLC Main Workbench Version 6.7.1 and translation of nucleotide sequence to amino acid sequences and editing were done using MEGA 7.0.4 software. A P-value of ≤ 0.05 was considered statistically significant. Transcript level determination and allelic discrimination analyses were done with the Bio-Rad CFX96 manager software (Additional file 2).

Results

Demographics

In this study, 83 patients, 36 (43.37%) male and 47 (56.63%) females presenting with symptoms of malaria were recruited for the study (Additional file 1: Table S3). The age distribution was as follows; 6 (0–5 years), 34 (6–19 years) 25 (20–35 years) and 18 were > 35 years.

mRNA transcript levels and polymorphisms in Pfk13 and PfATPase6 genes

Following confirmation of all RDT positive samples as *P. falciparum* positive by PCR, we carried out gene expression, detecting only wild type *Pfk13* transcript in


samples. Relatively low levels of *PfATPase6* transcript was also detected with both wild and mutant strains identified in the population (Fig. 1). Probe-specific allelic discrimination, detected both wild type and mutant *PfATPase6* alleles at known drug resistance SNPs (Fig. 2). For *Pfk13* C580Y locus, mixed alleles (both 580C and 580Y) were suspected in 2 isolates but the mutant type variant was not confirmed by Sanger sequencing of amplicons against the reference strain *P. falciparum* 3D7. K13 sequence identified eight non-synonymous SNPs in *Pfk13*, but all in single isolates. A deletion variant A557 was identified in 3.61% of isolates sequenced (Additional file 1: Table S4).



Distribution and prevalence of PfATPase6, Pfmdr 1 and Pfcrt polymorphisms

Sequence analysis of *PfATPase6* revealed 3 SNPs, one synonymous and two non-synonymous mutations (Additional file 1: Table S4). The ACT resistance related SNP (S769) was present in 3.6% of samples. *Pfmdr1* wildtype N86 allele was present in 56% of isolates sequenced. *Pfmdr1* Y184 was at much lower prevalence of 13.25% (Additional file 1: Table S4). *Pfcrt* 72–76 variants were translated, and haplotypes inferred. The CVIET haplotype associated with CQ resistance had a prevalence of 45%, while the wildtype CVMNK was found in 55% of isolates from the population (Fig. 3).

Discussion

Chemotherapy is one of the main malaria control strategies implemented by the National Malaria Control program in Nigeria. Today, it is mostly based on first line Artemisinin based combination therapy that was introduced into Nigeria in 2005 following the withdrawal of CQ and SP due to widespread resistance. Hence, there is





need to continuously monitor drug resistance and genetic markers that are associated with reduced drug efficacy. This study characterized drug resistance associated polymorphism in four different *P. falciparum* drug resistance genes; *Pfcrt*, *Pfmdr1*, *PfATPase6* and *Pfk13* that have been implicated in reduced ACT efficacy [2, 3, 9, 14]. As expression of mutated genes is needed for generating the resistance phenotype, the allele specific mRNA transcript levels of *Pfk13* and *PfATPase6* were also determined.

Most isolates expressed the wild type *Pfk13* while both the wild and mutant *PfATPase6* variants were expressed by different strains. Though *Pfk13* C580Y mutant allele was suspected in two mixed infections, only wildtype mRNA was detected. These mutant variants might have been from a minority strain whose mRNA expression

might have been masked by predominant *Pfk13* wildtype parasites in the infections. In the absence of repeated detection and confirmation by sequencing, the possibility of the detected *Pfk13* C580Y mutants being as a result of contamination cannot be ruled out. ACTs have been in use for 15 years in Nigeria, and the classical South East Asian *Pfk13* artemisinin resistance markers are rare in Africa. However, the possibility of the *Pfk13* 580Y resistance mutations is a call for concern, requiring further sampling and analysis of this population. The *Pfk13* C580Y mutant is the most prevalent SNP associated with reduction in parasite susceptibility to ACTs. Only few cases of delayed clearance of malaria after ACT treatment have been reported in Africa and the C580Y is almost completely absent. A recent ACT therapeutic

efficacy study with patients from the same populations detected persistent parasites 3 days post treatment but no *Pfk13* artemisinin resistance associated mutants [15]. Future enlarged studies including in vivo and in vitro assessments, genetically characterising local parasite isolates may throw light on any possible emergence of tolerance to ACT components. Though genetic epidemiology and in vitro forward genetic approaches have clearly implicated C580Y and other *Pfk13* mutations in delayed parasite clearance [16, 17], the artemisinin resistance phenotype and associated molecular mechanisms may be different in African parasites lacking these *Pfk13* variants. However, a recent report from Rwanda confirmed de novo local emergence and spread of the *Pfk13* R561H artemisinin resistance associated variant, though clinical cure rate remained >95% [18]. Other *Pfk13* haplotypes containing mutations at positions A578S and V581E, close to the C580Y mutation, are known to circulate in Africa and could have emerged prior to the introduction of ACTs [19]. Overall, any molecular indicators of resistance to artemisinins should be taken seriously and carefully monitored to prevent selection and spread of fit resistant parasites across Africa, which heavily relies on drugs against high levels of infection and morbidity.

We also detected polymorphisms of *PfATPase6*, the R₃₇K, A₆₃₀S, I₈₉8I found in Brazil, double mutation E431K, A623E in Senegal, and H₂₄₃Y in Central Africa. The *PfATPase6* S769 SNP we detected has been widely reported as a potential molecular marker for *P. falciparum* resistance to artemether [20]. This SNP is found within the cytoplasmic N (nucleotide binding) domain close to the conserved hinge, which in many species is important for structural transitions in the *PfATPase* cycle, calcium binding and release [14].

Other well-known characterized mutations in drug resistant genes such as *Pfmdr1*- N86Y and Y184E, and *pfprt*- CVIET haplotype were also detected. Polymorphisms of *Pfmdr1* (N86Y, Y184E, S1034C, N1042D, and D1246Y) and copy number amplifications modulate resistance to quinolones and other ACT partner drugs. They have been associated with reduced efficacy of artemether-lumefantrine/mefloquine combinations [21]. Artemether-Lumefantrine is the most common ACT combination in Africa and Nigeria. It selects for wildtype N86 and mutant Y184, as shown for other populations in West Africa [22].

Surprisingly a high prevalence of the CVIET haplotype was recorded despite the withdrawal of CQ from the population almost 10 years prior to this study. The high prevalence (45%) observed for *Pfprt*-76T resistance marker in southwest Nigeria is however lower than those reported from the south-eastern part of the country, where prevalence was as high as 75% [23]. Lumefantrine

selects for wildtype *Pfprt* K76, reversing CQ resistance that is strongly linked to the CVIET haplotype [3]. This reversal to the CQ susceptible CVMNK wild type haplotype following CQ withdrawal has been reported across many malaria endemic regions; in China [24], Tanzania [25], Kenya [26] and Malawi [27], or following malaria decline as observed in Ghana [28]. Exception are only seen in countries like Ethiopia (29) where CQ is still being administered to treat *P. vivax*, maintaining CQ pressure on the parasite to retain the resistant haplotypes. In Nigeria, CQ remains accessible through private drug suppliers together with amodiaquine, both of which could be slowing the reversal of the resistant haplotype in the population.

This study provides a molecular profile of the drug resistance genes in malaria parasites from South Western Nigeria, highlighting the need for continuous and broader surveillance for antimalarial resistance of this high malaria prevalent population.

Limitations

Our limited study locations and sample size is not sufficient to detect emerging resistance loci that may be at low frequencies in the populations. Due to limited availability of sampled DNA and RNA, we were unable to repeat the detection of the suspected C580Y mutant or validate its presence using sequencing approaches.

Supplementary information

Supplementary information accompanies this paper at <https://doi.org/10.1186/s13104-020-05334-5>.

Additional file 1: Table S1. List of primers and cycling conditions for amplification. **Table S2.** Taqman primers and probes. **Table S3.** Demographics of respondents. **Table S4.** Description of *Pfk13*, *PfATPase* and *Pfmdr1* polymorphisms. **Figure S1.** Allelic discrimination of K13 single nucleotide polymorphisms (SNPs).

Additional file 2. Allelic discrimination.

Abbreviations

ART: Artemisinin; ACT: Artemisinin combination therapy; CQ: Chloroquine; SSA: Sub Saharan Africa; PCR: Polymerase chain reaction; NPC: National population commission; SNP: Single nucleotide polymorphisms.

Acknowledgements

We wish to acknowledge all the parents and participants of this study including the management and staff of the hospitals where samples were collected (especially the laboratory scientist) and the support of laboratory staff at the Public Health Division of the Nigerian Institute of Medical Research and MRCG at LSHTM The Gambia.

Authors' contributions

MT designed the study, performed experiments, analysed the data and wrote the first draft of the manuscript. OA wrote the manuscript, analysed the data and edited the final draft of the manuscript. ETI and STA, designed the study, supervised and approved the final draft. AAN designed the study, analysed the data, provided resources for the research and edited. All authors read and approved the final manuscript.

Funding

This doctoral research work of Dr. Tola Monday was supported by funds from an MRC Career Development fellowship (Award MR/K02440X/1) to Dr. Alfred Amambua Ngwa through the WT/MRC/DFID/EDCTP Global Health Scheme.

Availability of data and materials

Data generated or analysed during this study are included in this published article (and its Additional files: 1, 2).

Ethics approval and consent to participate

Ethical approval for this study, IRB/13/218 was approved by the Institutional Review Board of the Nigerian Institute of Medical Research, Yaba, Lagos, Nigeria. Written informed parent or guardian consent was obtained from all participants in the study. All individuals positive for malaria were treated with Artemether-Lumefantrine by a nurse or clinician.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹ Public Health Division, Nigerian Institute of Medical Research, Lagos, Nigeria. ² First Technical University, Ibadan, Oyo State, Nigeria. ³ Department of Zoology, University of Lagos, Lagos, Nigeria. ⁴ Department of Cell Biology and Genetics, University of Lagos, Lagos, Nigeria. ⁵ Medical Research Council Unit The Gambia At London, School of Hygiene and Tropical Medicine, Banjul, The Gambia.

Received: 15 June 2020 Accepted: 14 October 2020

Published online: 27 October 2020

References

- World Health Organisation. Malaria [Internet]. 2020. <https://www.who.int/news-room/fact-sheets/detail/malaria>.
- Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of Artemisinin Resistance in *Plasmodium falciparum* Malaria. *N Engl J Med*. 2014;371(5):411–23.
- Djimé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diouré Y, et al. A molecular marker for Chloroquine-Resistant *Falciparum* Malaria. *N Engl J Med*. 2001;344(4):257–63.
- Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the *P. falciparum* digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. *Mol Cell*. 2000;6(4):861–71.
- Kublin JG, Dzinjalama FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria. *J Infect Dis*. 2002;185(3):380–8.
- van Eijk AM, Larsen DA, Kayentao K, Koshy G, Slaughter DEC, Roper C, et al. Effect of *Plasmodium falciparum* sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: a systematic review and meta-analysis. *Lancet Infect Dis*. 2019. <https://linkinghub.elsevier.com/retrieve/pii/S1473309918307321>. Accessed 4 Apr 2019
- Genotype K. Association of mutations in the *Plasmodium falciparum* Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments—a WWARN individual patient data meta-analysis. *BMC Med*. 2019;17(1):1.
- Adams T, Ennoson NAA, Quashie NB, Futagbi G, Matrevi S, Hagan OCK, et al. Prevalence of *Plasmodium falciparum* delayed clearance associated polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubp1) genes in Ghanaian isolates. *Parasit Vectors*. 2018;11(1):175.
- Borrmann S, Sasi P, Mwai L, Bashraheil M, Abdallah A, Muriithi S, et al. Declining responsiveness of *Plasmodium falciparum* infections to artemisinin-based combination treatments on the Kenyan Coast Mueller I, editor. *PLoS ONE*. 2011;6(11):e26005.
- Uhlemann A-C, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. *Nat Struct Mol Biol*. 2005;12(7):628–9.
- Eckstein-Ludwig U, Webb RJ, van Goethem IDA, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of *Plasmodium falciparum*. *Nature*. 2003;424(6951):957–61.
- Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. The tyrosine-86 allele of the pfmdr1 gene of *Plasmodium falciparum* is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. *Mol Biochem Parasitol*. 2000;108(1):13–23.
- Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. *Mol Biochem Parasitol*. 1993;58(2):283–92.
- Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of *Plasmodium falciparum* field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. *The Lancet*. 2005;366(9501):1960–3.
- Oyebola KM, Aina OO, Idowu ET, Olukosi YA, Ajibaye OS, Otubanjo OA, et al. A barcode of multilocus nuclear DNA identifies genetic relatedness in pre- and post-Artemether/Lumefantrine treated *Plasmodium falciparum* in Nigeria. *BMC Infect Dis*. 2018;18(1):392.
- Straimer J, Gnadig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, et al. K13-propeller mutations confer artemisinin resistance in *Plasmodium falciparum* clinical isolates. *Science*. 2015;347(6220):428–31.
- Ghorbal M, Gorman M, Macpherson CR, Martins RM, Scherf A, Lopez-Rubio J-J. Genome editing in the human malaria parasite *Plasmodium falciparum* using the CRISPR-Cas9 system. *Nat Biotechnol*. 2014;32(8):819–21.
- Uwimana A, Legrand E, Stokes BH, Ndikumana J-LM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda. *Nat Med*. 2020. <https://www.nature.com/articles/s41591-020-1005-2>. Accessed 19 Aug 2020
- Ouattara A, Kone A, Adams M, Fofana B, Maiga AW, Hampton S, et al. Polymorphisms in the K13-propeller gene in artemisinin-susceptible *Plasmodium falciparum* parasites from Bougoula-Hameau and Bandiagara. *Mali Am J Trop Med Hyg*. 2015;92(6):1202–6.
- Pillai DR, Lau R, Khairnar K, Lepore R, Via A, Staines HM, et al. Artemether resistance in vitro is linked to mutations in PfATP6 that also interact with mutations in PfMDR1 in travellers returning with *Plasmodium falciparum* infections. *Malar J*. 2012;11(1):131.
- Foote SJ, Kyle DE, Martin RK, Oduola AMJ, Forsyth K, Kemp DJ, et al. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in *Plasmodium falciparum*. *Nature*. 1990;345(6272):255–8.
- Amambua-Ngwa A, Okebe J, Mbye H, Ceessay S, El-Fatouri F, Joof F, et al. Sustained *Ex Vivo* Susceptibility of *Plasmodium falciparum* to Artemisinin Derivatives but Increasing Tolerance to Artemisinin Combination Therapy Partner Quinolines in The Gambia. *Antimicrob Agents Chemother*. 2017;61(12). <https://aac.asm.org/lookup/doi/10.1128/AAC.00759-17>. Accessed 17 Mar 2019
- Ikegbunam MN, Nkonganyi CN, Thomas BN, Esimone CO, Velavan TP, Ojuronbe O. Analysis of *Plasmodium falciparum* PfCRT and PfMDR1 genes in parasite isolates from asymptomatic individuals in Southeast Nigeria 11 years after withdrawal of chloroquine. *Malar J*. 2019;18(1):343.
- Wang X, Mu J, Li G, Chen P, Guo X, Fu L, et al. Decreased prevalence of the *Plasmodium falciparum* chloroquine resistance transporter 76T marker associated with cessation of chloroquine use against *P. falciparum* malaria in Hainan, People's Republic of China. *Am J Trop Med Hyg*. 2005;72(4):410–4.
- Mohammed A, Ndaró A, Kalinga A, Manjurano A, Mosha JF, Mosha DF, et al. Trends in chloroquine resistance marker, PfCRT-K76T mutation ten years after chloroquine withdrawal in Tanzania. *Malar J*. 2013;12(1):415.
- Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, et al. Chloroquine resistance before and after its withdrawal in Kenya. *Malar J*. 2009;8(1):106.
- Kublin JG, Cortese JF, Njunju EM, G Mukadam RA, Wirima JJ, Kazembe PN, et al. Reemergence of Chloroquine-Sensitive *Plasmodium falciparum* Malaria after Cessation of Chloroquine Use in Malawi. *J Infect Dis*. 2003;187(12):1870–5.

28. Alam MT, de Souza DK, Vinayak S, Griffing SM, Poe AC, Duah NO, et al. Selective Sweeps and Genetic Lineages of *Plasmodium falciparum* Drug-Resistant Alleles in Ghana. *J Infect Dis.* 2011;203(2):220–7.
29. Golassa L, Enweji N, Erko B, Aseffa A, Swedberg G. High prevalence of pfcr-t-CVIET haplotype in isolates from asymptomatic and symptomatic patients in south-central Oromia, Ethiopia. *Malar J.* 2014;13(1):120.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

